Bolt Biotherapeutics, Inc.
BOLT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001641281
In the last 90 days, Bolt Biotherapeutics, Inc. insiders filed 2 open-market purchases and 3 sales; 23 institutions reported holding it in 13F filings for Q2 2026, worth $2.31M in total; no superinvestor holds it.
13F holders, Q1 2024
Institutional positions in Bolt Biotherapeutics, Inc. as of Mar 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 39
- −1 vs. Q4 2023
- Shares held
- 24.0M
- −124.9K (−0.5%) vs. Q4 2023
- Total value
- $33.6M
- +$6.58M (+24.4%) vs. Q4 2023
- New holders
- 2
- 8 more added
- Sold out
- 3
- 12 more reduced
Compare with Q4 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting BOLT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 23 | $2.31M |
| Q1 2026 | 24 | $2.49M |
| Q4 2025 | 21 | $3.30M |
| Q3 2025 | 24 | $4.28M |
| Q2 2025 | 25 | $5.10M |
| Q1 2025 | 30 | $7.33M |
| Q4 2024 | 38 | $9.99M |
| Q3 2024 | 32 | $12.2M |
| Q2 2024 | 37 | $17.0M |
| Q1 2024 | 39 | $33.6M |
| Q4 2023 | 40 | $27.0M |
| Q3 2023 | 35 | $25.5M |
| Q2 2023 | 40 | $32.1M |
| Q1 2023 | 41 | $32.4M |
| Q4 2022 | 44 | $26.8M |
| Q3 2022 | 56 | $39.7M |
| Q2 2022 | 62 | $54.8M |
| Q1 2022 | 66 | $79.3M |
| Q4 2021 | 62 | $164.6M |
| Q3 2021 | 72 | $449.1M |
| Q2 2021 | 61 | $513.8M |
| Q1 2021 | 70 | $1.04B |
Institutions, Q1 2024
Shares, value and share of portfolio for each institution holding Bolt Biotherapeutics, Inc.; share changes are against Q4 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 1 | $0 | 0.00% | −464−99.8% | Reduced |
| Qube Research & Technologies Ltd | 2 | $3 | 0.00% | 00.0% | Unchanged |
| Salem Investment Counselors Inc | 40 | $56 | 0.00% | 00.0% | Unchanged |
| Barclays PLC | 139 | $195 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 211 | $295 | 0.00% | +4+1.9% | Added |
| Bank of America Corp | 628 | $879 | 0.00% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 840 | $1.18K | 0.00% | 00.0% | Unchanged |
| ADAR1 Capital Management, LLC | 5,000 | $7.00K | 0.00% | +5,000 | New |
| Tower Research Capital LLC (TRC) | 5,546 | $7.76K | 0.00% | −2,690−32.7% | Reduced |
| Virtu Financial LLC | 10,938 | $15.0K | 0.00% | +10,938 | New |
| UBS Group AG | 12,171 | $17.0K | 0.00% | +4,520+59.1% | Added |
| XTX Topco Ltd | 12,826 | $18.0K | 0.00% | −6,326−33.0% | Reduced |
| Advisor Group Holdings, Inc. | 15,000 | $21.0K | 0.00% | +11,022+277.1% | Added |
| Two Sigma Securities, LLC | 23,814 | $33.3K | 0.00% | −40,418−62.9% | Reduced |
| Morgan Stanley | 24,687 | $34.6K | 0.00% | −54,707−68.9% | Reduced |
| Prudential Financial Inc | 35,200 | $49.3K | 0.00% | +23,000+188.5% | Added |
| Northern Trust Corp | 41,005 | $57.4K | 0.00% | 00.0% | Unchanged |
| Millennium Management LLC | 45,956 | $64.3K | 0.00% | −1,051−2.2% | Reduced |
| State Street Corp | 47,437 | $66.4K | 0.00% | 00.0% | Unchanged |
| Squarepoint Ops LLC | 78,020 | $109.2K | 0.00% | −1,752−2.2% | Reduced |
| FMR LLC | 78,899 | $110.5K | 0.00% | −294−0.4% | Reduced |
| Marquette Asset Management, LLC | 96,673 | $135.3K | 0.02% | 00.0% | Unchanged |
| Bridgeway Capital Management, LLC | 111,200 | $155.7K | 0.00% | 00.0% | Unchanged |
| BlackRock Inc. | 254,958 | $356.9K | 0.00% | −2,313−0.9% | Reduced |
| Geode Capital Management, LLC | 347,567 | $486.7K | 0.00% | −2,597−0.7% | Reduced |
| Adage Capital Partners GP, L.L.C. | 500,000 | $700.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 517,637 | $725.0K | 0.00% | +72,364+16.3% | Added |
| Acuitas Investments, LLC | 517,952 | $725.1K | 0.37% | +58,497+12.7% | Added |
| Board of Trustees of The Leland Stanford Junior University | 719,546 | $1.01M | 0.09% | 00.0% | Unchanged |
| Vanguard Group Inc | 1,037,603 | $1.45M | 0.00% | +106,474+11.4% | Added |
| Samsara BioCapital, LLC | 1,049,153 | $1.47M | 0.23% | 00.0% | Unchanged |
| Nan Fung Group Holdings Ltd | 1,166,952 | $1.63M | 1.51% | 00.0% | Unchanged |
| OrbiMed Advisors LLC | 1,541,000 | $2.16M | 0.04% | 00.0% | Unchanged |
| Newtyn Management, LLC | 1,700,000 | $2.38M | 0.47% | +146,465+9.4% | Added |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,891,467 | $2.65M | 1.70% | 00.0% | Unchanged |
| Citadel Advisors LLC | 2,415,728 | $3.38M | 0.00% | −43,230−1.8% | Reduced |
| Sofinnova Investments, Inc. | 2,754,437 | $3.86M | 0.23% | 00.0% | Unchanged |
| Tang Capital Management LLC | 3,420,000 | $4.79M | 0.50% | −232,244−6.4% | Reduced |
| Vivo Capital, LLC | 3,521,291 | $4.93M | 0.39% | 00.0% | Unchanged |
| Privium Fund Management (UK) Ltd | 0 | $0 | 0.00% | −116,516−100.0% | Sold out |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −56,264−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −2,307−100.0% | Sold out |